Cargando…

Drug Resistance (Dapsone, Rifampicin, Ofloxacin) and Resistance-Related Gene Mutation Features in Leprosy Patients: A Systematic Review and Meta-Analysis

Dapsone (DDS), Rifampicin (RIF) and Ofloxacin (OFL) are drugs recommended by the World Health Organization (WHO) for the treatment of leprosy. In the context of leprosy, resistance to these drugs occurs mainly due to mutations in the target genes (Folp1, RpoB and GyrA). It is important to monitor an...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiang, Li, Guoli, Yang, Jing, Jin, Guangjie, Shao, Yuting, Li, Yunhui, Wei, Pingmin, Zhang, Lianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604410/
https://www.ncbi.nlm.nih.gov/pubmed/36293307
http://dx.doi.org/10.3390/ijms232012443
_version_ 1784817807267987456
author Li, Xiang
Li, Guoli
Yang, Jing
Jin, Guangjie
Shao, Yuting
Li, Yunhui
Wei, Pingmin
Zhang, Lianhua
author_facet Li, Xiang
Li, Guoli
Yang, Jing
Jin, Guangjie
Shao, Yuting
Li, Yunhui
Wei, Pingmin
Zhang, Lianhua
author_sort Li, Xiang
collection PubMed
description Dapsone (DDS), Rifampicin (RIF) and Ofloxacin (OFL) are drugs recommended by the World Health Organization (WHO) for the treatment of leprosy. In the context of leprosy, resistance to these drugs occurs mainly due to mutations in the target genes (Folp1, RpoB and GyrA). It is important to monitor antimicrobial resistance in patients with leprosy. Therefore, we performed a meta-analysis of drug resistance in Mycobacterium leprae and the mutational profile of the target genes. In this paper, we limited the study period to May 2022 and searched PubMed, Web of Science (WOS), Scopus, and Embase databases for identified studies. Two independent reviewers extracted the study data. Mutation and drug-resistance rates were estimated in Stata 16.0. The results demonstrated that the drug-resistance rate was 10.18% (95% CI: 7.85–12.51). Subgroup analysis showed the highest resistance rate was in the Western Pacific region (17.05%, 95% CI:1.80 to 13.78), and it was higher after 2009 than before [(11.39%, 7.46–15.33) vs. 6.59% (3.66–9.53)]. We can conclude that the rate among new cases (7.25%, 95% CI: 4.65–9.84) was lower than the relapsed (14.26%, 95 CI%: 9.82–18.71). Mutation rates of Folp1, RpoB and GyrA were 4.40% (95% CI: 3.02–5.77), 3.66% (95% CI: 2.41–4.90) and 1.28% (95% CI: 0.87–1.71) respectively, while the rate for polygenes mutation was 1.73% (0.83–2.63). For further analysis, we used 368 drug-resistant strains as research subjects and found that codons (Ser, Pro, Ala) on RpoB, Folp1 and GyrA are the most common mutation sites in the determining region (DRDR). In addition, the most common substitution patterns of Folp1, RpoB, and GyrA are Pro→Leu, Ser→Leu, and Ala→Val. This study found that a higher proportion of patients has developed resistance to these drugs, and the rate has increased since 2009, which continue to pose a challenge to clinicians. In addition, the amino acid alterations in the sequence of the DRDR regions and the substitution patterns mentioned in the study also provide new ideas for clinical treatment options.
format Online
Article
Text
id pubmed-9604410
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96044102022-10-27 Drug Resistance (Dapsone, Rifampicin, Ofloxacin) and Resistance-Related Gene Mutation Features in Leprosy Patients: A Systematic Review and Meta-Analysis Li, Xiang Li, Guoli Yang, Jing Jin, Guangjie Shao, Yuting Li, Yunhui Wei, Pingmin Zhang, Lianhua Int J Mol Sci Review Dapsone (DDS), Rifampicin (RIF) and Ofloxacin (OFL) are drugs recommended by the World Health Organization (WHO) for the treatment of leprosy. In the context of leprosy, resistance to these drugs occurs mainly due to mutations in the target genes (Folp1, RpoB and GyrA). It is important to monitor antimicrobial resistance in patients with leprosy. Therefore, we performed a meta-analysis of drug resistance in Mycobacterium leprae and the mutational profile of the target genes. In this paper, we limited the study period to May 2022 and searched PubMed, Web of Science (WOS), Scopus, and Embase databases for identified studies. Two independent reviewers extracted the study data. Mutation and drug-resistance rates were estimated in Stata 16.0. The results demonstrated that the drug-resistance rate was 10.18% (95% CI: 7.85–12.51). Subgroup analysis showed the highest resistance rate was in the Western Pacific region (17.05%, 95% CI:1.80 to 13.78), and it was higher after 2009 than before [(11.39%, 7.46–15.33) vs. 6.59% (3.66–9.53)]. We can conclude that the rate among new cases (7.25%, 95% CI: 4.65–9.84) was lower than the relapsed (14.26%, 95 CI%: 9.82–18.71). Mutation rates of Folp1, RpoB and GyrA were 4.40% (95% CI: 3.02–5.77), 3.66% (95% CI: 2.41–4.90) and 1.28% (95% CI: 0.87–1.71) respectively, while the rate for polygenes mutation was 1.73% (0.83–2.63). For further analysis, we used 368 drug-resistant strains as research subjects and found that codons (Ser, Pro, Ala) on RpoB, Folp1 and GyrA are the most common mutation sites in the determining region (DRDR). In addition, the most common substitution patterns of Folp1, RpoB, and GyrA are Pro→Leu, Ser→Leu, and Ala→Val. This study found that a higher proportion of patients has developed resistance to these drugs, and the rate has increased since 2009, which continue to pose a challenge to clinicians. In addition, the amino acid alterations in the sequence of the DRDR regions and the substitution patterns mentioned in the study also provide new ideas for clinical treatment options. MDPI 2022-10-18 /pmc/articles/PMC9604410/ /pubmed/36293307 http://dx.doi.org/10.3390/ijms232012443 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Li, Xiang
Li, Guoli
Yang, Jing
Jin, Guangjie
Shao, Yuting
Li, Yunhui
Wei, Pingmin
Zhang, Lianhua
Drug Resistance (Dapsone, Rifampicin, Ofloxacin) and Resistance-Related Gene Mutation Features in Leprosy Patients: A Systematic Review and Meta-Analysis
title Drug Resistance (Dapsone, Rifampicin, Ofloxacin) and Resistance-Related Gene Mutation Features in Leprosy Patients: A Systematic Review and Meta-Analysis
title_full Drug Resistance (Dapsone, Rifampicin, Ofloxacin) and Resistance-Related Gene Mutation Features in Leprosy Patients: A Systematic Review and Meta-Analysis
title_fullStr Drug Resistance (Dapsone, Rifampicin, Ofloxacin) and Resistance-Related Gene Mutation Features in Leprosy Patients: A Systematic Review and Meta-Analysis
title_full_unstemmed Drug Resistance (Dapsone, Rifampicin, Ofloxacin) and Resistance-Related Gene Mutation Features in Leprosy Patients: A Systematic Review and Meta-Analysis
title_short Drug Resistance (Dapsone, Rifampicin, Ofloxacin) and Resistance-Related Gene Mutation Features in Leprosy Patients: A Systematic Review and Meta-Analysis
title_sort drug resistance (dapsone, rifampicin, ofloxacin) and resistance-related gene mutation features in leprosy patients: a systematic review and meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604410/
https://www.ncbi.nlm.nih.gov/pubmed/36293307
http://dx.doi.org/10.3390/ijms232012443
work_keys_str_mv AT lixiang drugresistancedapsonerifampicinofloxacinandresistancerelatedgenemutationfeaturesinleprosypatientsasystematicreviewandmetaanalysis
AT liguoli drugresistancedapsonerifampicinofloxacinandresistancerelatedgenemutationfeaturesinleprosypatientsasystematicreviewandmetaanalysis
AT yangjing drugresistancedapsonerifampicinofloxacinandresistancerelatedgenemutationfeaturesinleprosypatientsasystematicreviewandmetaanalysis
AT jinguangjie drugresistancedapsonerifampicinofloxacinandresistancerelatedgenemutationfeaturesinleprosypatientsasystematicreviewandmetaanalysis
AT shaoyuting drugresistancedapsonerifampicinofloxacinandresistancerelatedgenemutationfeaturesinleprosypatientsasystematicreviewandmetaanalysis
AT liyunhui drugresistancedapsonerifampicinofloxacinandresistancerelatedgenemutationfeaturesinleprosypatientsasystematicreviewandmetaanalysis
AT weipingmin drugresistancedapsonerifampicinofloxacinandresistancerelatedgenemutationfeaturesinleprosypatientsasystematicreviewandmetaanalysis
AT zhanglianhua drugresistancedapsonerifampicinofloxacinandresistancerelatedgenemutationfeaturesinleprosypatientsasystematicreviewandmetaanalysis